Corient Private Wealth LP Invests $2.19 Million in Sana Biotechnology, Inc. $SANA

Key Points

• Corient Private Wealth LP acquired 628,200 shares of Sana Biotechnology worth approximately $2.19 million, representing a 0.21% stake.
• Several major institutions, including BlackRock, Canada Pension Plan Investment Board, Bank of America and Alphabet, also initiated positions. Institutional investors collectively own 88.23% of Sana’s stock.
• Sana shares opened at $3.89, while analysts maintain a consensus “Moderate Buy” rating with an average price target of $9.33. The company recently reported a quarterly loss of $0.13 per share, beating estimates.

Corient Private Wealth LP purchased a new position in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 628,200 shares of the company's stock, valued at approximately $2,192,000. Corient Private Wealth LP owned 0.21% of Sana Biotechnology at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in SANA. BlackRock Inc. purchased a new position in shares of Sana Biotechnology during the second quarter worth approximately $58,196,000. Canada Pension Plan Investment Board purchased a new stake in shares of Sana Biotechnology in the second quarter valued at approximately $35,662,000. Bank of America Corp DE bought a new position in Sana Biotechnology in the second quarter worth approximately $20,062,000. Alphabet Inc. bought a new position in Sana Biotechnology in the second quarter worth approximately $9,816,000. Finally, Balyasny Asset Management L.P. purchased a new position in Sana Biotechnology during the 4th quarter worth $6,834,000. 88.23% of the stock is owned by hedge funds and other institutional investors.

Sana Biotechnology Price Performance

Shares of NASDAQ SANA opened at $3.89 on Thursday. The stock has a market capitalization of $1.16 billion, a P/E ratio of -5.12 and a beta of 2.12. Sana Biotechnology, Inc. has a 1-year low of $2.61 and a 1-year high of $6.55. The business has a fifty day moving average price of $3.60 and a 200 day moving average price of $3.41.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.02. As a group, equities research analysts anticipate that Sana Biotechnology, Inc. will post -0.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

SANA has been the subject of a number of research analyst reports. Bank of America decreased their target price on Sana Biotechnology from $7.00 to $6.00 and set a "buy" rating for the company in a research report on Friday, August 14th. Wall Street Zen downgraded Sana Biotechnology from a "hold" rating to a "sell" rating in a research report on Monday, July 20th. Rodman & Renshaw started coverage on Sana Biotechnology in a research note on Monday, May 11th. They set a "buy" rating and a $16.00 price target on the stock. Weiss Ratings upgraded Sana Biotechnology from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, July 23rd. Finally, TD Cowen raised shares of Sana Biotechnology to a "strong-buy" rating in a research note on Monday, August 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $9.33.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company's core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.

Want to see what other hedge funds are holding SANA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source